Immutep Quarterly Activities Report
TACTI-002 study expanded in lung cancer New phase II trial in head and neck cancer announced EOC Pharma starts new phase II study in metastatic breast cancer Robust operational and financial position, with $54.9 million in cash as at 31 December 2020, providing cash runway beyond the end of calendar year 2022 Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its ...
Source: globenewswire.com